EpiPen rival Symjepi is one step closer to U.S. rollout after striking commercial-rights deal with Novartishttps://on.wsj.com/2yXP2pz
4 replies
28 retweets
65 likes
Loading seems to be taking a while.
Twitter may be over capacity or experiencing a momentary hiccup. Try again or visit Twitter Status for more information.